These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 27001444)

  • 1. First Clinical Experience with ONO-4232: A Randomized, Double-blind, Placebo-controlled Healthy Volunteer Study of a Novel Lusitropic Agent for Acutely Decompensated Heart Failure.
    Ward CL; Jamieson V; Nabata T; Sharpe J; Dozono K; Suto F; Hashimoto Y; Gussak I
    Clin Ther; 2016 May; 38(5):1109-21. PubMed ID: 27001444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and pharmacokinetics of NXN-188 after single and multiple doses in five phase I, randomized, double-blind, parallel studies in healthy adult volunteers.
    Vaughan D; Speed J; Medve R; Andrews JS
    Clin Ther; 2010 Jan; 32(1):146-60. PubMed ID: 20171420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety, Tolerability, and Pharmacokinetic Profile of the Novel Translocator Protein 18 kDa Antagonist ONO-2952 in Healthy Volunteers.
    Suto F; Wood AT; Kobayashi M; Komaba J; Duffy K; Bruce M
    Clin Ther; 2015 Sep; 37(9):2071-84. PubMed ID: 26249232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of 8-hour intravenous infusion of NXY-059: a phase I, randomized, double-blind (within dose panels), placebo-controlled study in healthy Chinese volunteers.
    Cheng YF; Jiang J; Hu P; Reinholdsson I; Guo W; Asenblad N; Nilsson D
    Clin Ther; 2008 Dec; 30(12):2342-53. PubMed ID: 19167593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in volunteers with mild iron-deficiency anaemia.
    Geisser P; Banké-Bochita J
    Arzneimittelforschung; 2010; 60(6a):362-72. PubMed ID: 20648928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of the effects on blood pressure of abrupt cessation versus taper down of guanfacine extended-release tablets in adults aged 19 to 24 years.
    Kisicki JC; Fiske K; Lyne A
    Clin Ther; 2007 Sep; 29(9):1967-79. PubMed ID: 18035196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
    Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
    Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of a prostagrandin EP4-receptor agonist ONO-AE1-329 on the left ventricular pressure-volume relationship in the halothane-anesthetized dogs.
    Honda A; Nakamura Y; Ohara H; Cao X; Nomura H; Katagi J; Wada T; Izumi-Nakaseko H; Ando K; Sugiyama A
    Eur J Pharmacol; 2016 Mar; 775():130-7. PubMed ID: 26872985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel Mitochondria-Targeting Peptide in Heart Failure Treatment: A Randomized, Placebo-Controlled Trial of Elamipretide.
    Daubert MA; Yow E; Dunn G; Marchev S; Barnhart H; Douglas PS; O'Connor C; Goldstein S; Udelson JE; Sabbah HN
    Circ Heart Fail; 2017 Dec; 10(12):. PubMed ID: 29217757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clevidipine: a review of its use in the management of acute hypertension.
    Deeks ED; Keating GM; Keam SJ
    Am J Cardiovasc Drugs; 2009; 9(2):117-34. PubMed ID: 19331440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase 2a dose-escalation study of the safety, tolerability, pharmacokinetics and haemodynamic effects of BMS-986231 in hospitalized patients with heart failure with reduced ejection fraction.
    Tita C; Gilbert EM; Van Bakel AB; Grzybowski J; Haas GJ; Jarrah M; Dunlap SH; Gottlieb SS; Klapholz M; Patel PC; Pfister R; Seidler T; Shah KB; Zieliński T; Venuti RP; Cowart D; Foo SY; Vishnevsky A; Mitrovic V
    Eur J Heart Fail; 2017 Oct; 19(10):1321-1332. PubMed ID: 28677877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized, double-blind, placebo-controlled, multicenter, repeat-dose study of two intravenous acetaminophen dosing regimens for the treatment of pain after abdominal laparoscopic surgery.
    Wininger SJ; Miller H; Minkowitz HS; Royal MA; Ang RY; Breitmeyer JB; Singla NK
    Clin Ther; 2010 Dec; 32(14):2348-69. PubMed ID: 21353105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase 1, randomized study to evaluate safety, tolerability, and pharmacokinetics of GDC-3280, a potential novel anti-fibrotic small molecule, in healthy subjects.
    Cheung D; Fong A; Ding HT; Cabanski CR; Wang J; Chen Y; Bush J; Harris JM; Pan L
    Pulm Pharmacol Ther; 2021 Aug; 69():102051. PubMed ID: 34166834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tolerability, pharmacokinetics and concentration-dependent hemodynamic effects of oral CF101, an A3 adenosine receptor agonist, in healthy young men.
    van Troostenburg AR; Clark EV; Carey WD; Warrington SJ; Kerns WD; Cohn I; Silverman MH; Bar-Yehuda S; Fong KL; Fishman P
    Int J Clin Pharmacol Ther; 2004 Oct; 42(10):534-42. PubMed ID: 15516022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A population pharmacokinetic/pharmacodynamic analysis of regadenoson, an adenosine A2A-receptor agonist, in healthy male volunteers.
    Gordi T; Frohna P; Sun HL; Wolff A; Belardinelli L; Lieu H
    Clin Pharmacokinet; 2006; 45(12):1201-12. PubMed ID: 17112296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical pharmacology of DP-b99 in healthy volunteers: first administration to humans.
    Rosenberg G; Angel I; Kozak A
    Br J Clin Pharmacol; 2005 Jul; 60(1):7-16. PubMed ID: 15963088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Novel Dual Agonist of EP3 and FP Receptors for OAG and OHT: Safety, Pharmacokinetics, and Pharmacodynamics of ONO-9054 in Healthy Volunteers.
    Suto F; Rowe-Rendleman CL; Ouchi T; Jamil A; Wood A; Ward CL
    Invest Ophthalmol Vis Sci; 2015 Dec; 56(13):7963-70. PubMed ID: 26720443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic properties of mirabegron, a β3-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women.
    Krauwinkel W; van Dijk J; Schaddelee M; Eltink C; Meijer J; Strabach G; van Marle S; Kerbusch V; van Gelderen M
    Clin Ther; 2012 Oct; 34(10):2144-60. PubMed ID: 23063375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hemodynamic and humoral effects at rest and after head-up tilt tests during 24-hour infusion of a new nitrate ester, ITF 296, compared with ISDN and placebo in healthy volunteers: a double-blind, randomized, within-subject study.
    Sardina M; Warrington SJ; Boyce M; Johnston A; Bianchini C
    J Cardiovasc Pharmacol; 1995; 26 Suppl 4():S80-90. PubMed ID: 8839231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tolerability and pharmacokinetics of avanafil, a phosphodiesterase type 5 inhibitor: a single- and multiple-dose, double-blind, randomized, placebo-controlled, dose-escalation study in healthy Korean male volunteers.
    Jung J; Choi S; Cho SH; Ghim JL; Hwang A; Kim U; Kim BS; Koguchi A; Miyoshi S; Okabe H; Bae KS; Lim HS
    Clin Ther; 2010 Jun; 32(6):1178-87. PubMed ID: 20637970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.